DB:2E4

Stock Analysis Report

Executive Summary

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases.


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has ERYTECH Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2E4's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.8%

20000

3.3%

DE Biotechs

2.2%

DE Market


1 Year Return

-33.3%

20000

-11.2%

DE Biotechs

-17.2%

DE Market

Return vs Industry: 2E4 underperformed the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: 2E4 underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

20000IndustryMarket
7 Day4.8%3.3%2.2%
30 Day-5.9%-6.5%-15.7%
90 Day-14.6%-23.1%-24.0%
1 Year-33.3%-33.3%-11.0%-11.2%-14.9%-17.2%
3 Yearn/a14.9%13.6%-16.4%-23.3%
5 Yearn/a-8.0%-10.3%-16.5%-27.8%

Price Volatility Vs. Market

How volatile is ERYTECH Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ERYTECH Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2E4 (€4.83) is trading below our estimate of fair value (€13.22)

Significantly Below Fair Value: 2E4 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2E4 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2E4 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2E4's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2E4 is good value based on its PB Ratio (1.1x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is ERYTECH Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

34.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2E4 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2E4 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2E4 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2E4's revenue (63.4% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: 2E4's revenue (63.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2E4 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has ERYTECH Pharma performed over the past 5 years?

-32.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2E4 is currently unprofitable.

Growing Profit Margin: 2E4 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2E4 is unprofitable, and losses have increased over the past 5 years at a rate of -32.4% per year.

Accelerating Growth: Unable to compare 2E4's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2E4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 2E4 has a negative Return on Equity (-73.23%), as it is currently unprofitable.


Next Steps

Financial Health

How is ERYTECH Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 2E4's short term assets (€81.6M) exceed its short term liabilities (€19.9M).

Long Term Liabilities: 2E4's short term assets (€81.6M) exceed its long term liabilities (€13.1M).


Debt to Equity History and Analysis

Debt Level: 2E4's debt to equity ratio (1.7%) is considered satisfactory.

Reducing Debt: 2E4's debt to equity ratio has increased from 1.5% to 1.7% over the past 5 years.


Balance Sheet

Inventory Level: 2E4 has a high level of physical assets or inventory.

Debt Coverage by Assets: 2E4's debt is covered by short term assets (assets are 57.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2E4 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2E4 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is ERYTECH Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2E4's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2E4's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2E4's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2E4's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2E4's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Gil Beyen (57yo)

6.83s

Tenure

€790,711

Compensation

Mr. Gil Beyen, BVBA has been the Chief Executive Officer of Erytech Pharma Société Anonyme (formerly, ERYtech Pharma SA) since May 2013. For more than ten years, Mr. Beyen has been a Management Consultant  ...


CEO Compensation Analysis

Compensation vs Market: Gil's total compensation ($USD872.36K) is above average for companies of similar size in the German market ($USD431.45K).

Compensation vs Earnings: Gil's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Gil Beyen
CEO & Director6.83yrs€790.71k0.0086% 8.0k
Eric Soyer
CFO, COO & Deputy GM4.42yrs€453.63k0.0043% 4.0k
Jérôme Bailly
VP, Director of Pharmaceutical Operations & Deputy GMno data€287.66k0.0059% 5.5k
Alexander Scheer
Chief Scientific Officer3.42yrsno data0.014% 12.9k
Naomi Eichenbaum
Director Investor Relationsno datano datano data
Iman El-Hariry
Chief Medical Officer4.67yrsno datano data
Jean-Sébastien Cleiftie
Chief Business Officer3.42yrsno data0.0059% 5.5k
Philip Lorenzi
Consultant & Member of Scientific Board10.17yrsno datano data
Eric Raymond
Consultant & Member of Scientific Board10.42yrsno datano data
Bridget Bax
Consultant & Member of Scientific Board8.17yrsno datano data

4.4yrs

Average Tenure

55yo

Average Age

Experienced Management: 2E4's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gil Beyen
CEO & Director6.83yrs€790.71k0.0086% 8.0k
Philip Lorenzi
Consultant & Member of Scientific Board10.17yrsno datano data
Eric Raymond
Consultant & Member of Scientific Board10.42yrsno datano data
Bridget Bax
Consultant & Member of Scientific Board8.17yrsno datano data
Arthur Frankel
Consultant & Member of Scientific Board8.17yrsno datano data
Kurt Gunter
Consultant & Member of Scientific Board8.17yrsno datano data
Philippe Archinard
Independent Director6.83yrs€65.50k0.057% 53.6k
Sven Andréasson
Independent Director10.42yrs€59.00kno data
Hilde Windels
Independent Director5.42yrs€49.50k0.000010% 9.3
Jean-Paul Kress
Independent Chairman of the Board0.67yr€170.09kno data

8.2yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 2E4's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ERYTECH Pharma S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ERYTECH Pharma S.A.
  • Ticker: 20000
  • Exchange: DB
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €93.275m
  • Shares outstanding: 17.94m
  • Website: https://www.erytech.com

Number of Employees


Location

  • ERYTECH Pharma S.A.
  • 60 Avenue Rockefeller
  • Lyon
  • Rhône-Alpes
  • 69008
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ERYPENXTPA (Euronext Paris)YesCategory O SharesFREURApr 2013
ERYPPBATS-CHIXE (BATS 'Chi-X Europe')YesCategory O SharesGBEURApr 2013
0QSSLSE (London Stock Exchange)YesCategory O SharesGBEURApr 2013
20000DB (Deutsche Boerse AG)YesCategory O SharesDEEURApr 2013
ERYPNasdaqGS (Nasdaq Global Select)SPON ADR EACH REPR 1 ORDUSUSDMar 2015
2E4ADB (Deutsche Boerse AG)SPON ADR EACH REPR 1 ORDDEEURMar 2015

Biography

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. The company’s lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. ERYTECH Pharma S.A. has research collaboration with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen’s University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is headquartered in Lyon, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 00:14
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.